surmount-1 tirzepatide non-diabetic obesity trial Weight reduction with different doses of in Surmount 1 Tirzepatide proves to be more

This study incorporated data from participants first assessment with complete information through a maximum follow-up duration of 15 years

Bullous, Pustular, and Ulcerative Reactions Bullous pemphigoid (BP) is an autoimmune bullous disorder caused by the production of antibodies against hemidesmosomal proteins, primarily BP180 and BP230, which are essential for the adhesion of the epidermis to the dermis

This may help lighten the skin and improve its texture and color since it may hinder melanin synthesis, which leads to dark patches

Other options have since come on the market, including Zepbound (tirzepatide), which received FDA approval in November 2023